Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $993,313.10 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 41,302 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $24.05, for a total value of $993,313.10. Following the completion of the transaction, the insider owned 856,386 shares in the company, valued at $20,596,083.30. This represents a 4.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Enliven Therapeutics Stock Up 1.2%

Shares of Enliven Therapeutics stock opened at $26.05 on Thursday. The business has a fifty day simple moving average of $19.46 and a 200 day simple moving average of $20.05. The stock has a market cap of $1.55 billion, a PE ratio of -14.16 and a beta of 0.41. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $29.98.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. Analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its holdings in shares of Enliven Therapeutics by 30.2% in the third quarter. JPMorgan Chase & Co. now owns 24,818 shares of the company’s stock valued at $508,000 after buying an additional 5,754 shares during the period. Tudor Investment Corp ET AL bought a new stake in Enliven Therapeutics in the 3rd quarter valued at $334,000. Vestal Point Capital LP boosted its stake in Enliven Therapeutics by 364.0% in the 3rd quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock worth $23,745,000 after purchasing an additional 910,000 shares during the period. Polar Capital Holdings Plc boosted its stake in Enliven Therapeutics by 1.5% in the 3rd quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock worth $63,355,000 after purchasing an additional 44,713 shares during the period. Finally, Millennium Management LLC increased its holdings in Enliven Therapeutics by 19.8% during the 3rd quarter. Millennium Management LLC now owns 381,405 shares of the company’s stock worth $7,807,000 after purchasing an additional 62,956 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on ELVN. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.